6533b830fe1ef96bd12979da
RESEARCH PRODUCT
Topotecan (T) ± sorafenib (S) in platinum-resistant ovarian cancer (PROC): A double-blind placebo-controlled randomized NOGGO–AGO intergroup Trial—TRIAS.
Hans-joachim LueckRadoslav ChekerovSven MahnerJochem PotenbergFelix HilpertPhilipp HarterSusanne MarkmannPetra KrabischMarcus SchmidtAndreas Du BoisRolf RichterPeter KlareClaudius FridrichIsolde GroellTanja NeunhoefferGabriele DoeringNikolaus De GregorioRalf LorenzJalid SehouliAntje Belausubject
SorafenibOncologyCancer Researchmedicine.medical_specialty030219 obstetrics & reproductive medicineendocrine system diseasesmedicine.drug_classbusiness.industryPlacebomedicine.diseasefemale genital diseases and pregnancy complicationsDouble blind03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineToxicitymedicineTopotecanbusinessOvarian cancerTopoisomerase inhibitormedicine.drugPlatinum resistantdescription
5522Background: Sorafenib (S), a multi TK-inhibitor in combination with topotecan (T), a topoisomerase inhibitor showed preclinical synergistic effects in ovarian cancer but critical toxicity. To a...
year | journal | country | edition | language |
---|---|---|---|---|
2016-05-20 | Journal of Clinical Oncology |